Exploring Analyst Estimates for Gilead (GILD) Q4 Earnings, Beyond Revenue and EPS
Evaluate the expected performance of Gilead (GILD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...
Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus rises, Gilead slips on expanded agreement
Shares in Arcus Biosciences Inc rose after Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) agreed to invest another $320 million as part of a tweaked collaboration agreement. Extending a multiple-drug p...
Gilead Sciences raises stake in cancer-centric Arcus Biosciences to 33%
Gilead Sciences said on Monday it has raised its stake in Arcus Biosciences to 33% and expanded its presence in the drug developer's board to three, deepening their collaboration in developing canc...
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
Why Gilead Sciences Stock Got Mashed on Monday
Trodelvy did not perform well in an important clinical trial. Management is vowing to keep seeking other patient populations to treat with the drug.
Gilead shares plunge on lung cancer trial disappointment
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares fell by their most since 2015 as the late-stage trial of its antibody-drug conjugate Trodelvy failed to show a significant improvement in the overa...
Gilead stock falls after disappointing lung cancer study results
Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.
Gilead says its Trodelvy disappointed in a late-stage cancer trial
Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.
Gilead's stock tumbles toward biggest selloff in more than 9 years after lung cancer treatment trial disappoints
Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its ...
Gilead says Trodelvy fails to meet primary goal in 2nd-line lung cancer trial
Gilead Sciences on Monday said a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non-sm...
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
Can AI and a supercomputer beat the markets? This is one of the hedge funds trying to find out.
In a downtown Toronto skyscraper one block away from the Hockey Hall of Fame, a small hedge fund is hoping it has found an edge in financial markets. Castle Ridge Asset Management is betting on Wal...
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $85.39, denoting a +1.05% change from the preceding trading day.
Top Stock Picks for 2024: Gilead Sciences
Every day for the next three weeks, we're going to highlight one of Schaeffer's top 12 picks for 2024.
Related Companies